MX2009002471A - Metodo para evaluar a pacientes para tratamiento con farmacos que detectan la transfeccion durante el redondeamiento (ret) de tirosina cinasa receptora. - Google Patents

Metodo para evaluar a pacientes para tratamiento con farmacos que detectan la transfeccion durante el redondeamiento (ret) de tirosina cinasa receptora.

Info

Publication number
MX2009002471A
MX2009002471A MX2009002471A MX2009002471A MX2009002471A MX 2009002471 A MX2009002471 A MX 2009002471A MX 2009002471 A MX2009002471 A MX 2009002471A MX 2009002471 A MX2009002471 A MX 2009002471A MX 2009002471 A MX2009002471 A MX 2009002471A
Authority
MX
Mexico
Prior art keywords
treatment
tyrosine kinase
receptor tyrosine
drugs targeting
ret receptor
Prior art date
Application number
MX2009002471A
Other languages
English (en)
Inventor
Anderson Joseph Ryan
James Sherwood
Alan Wookey
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2009002471A publication Critical patent/MX2009002471A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un método para la selección de un paciente, que es un candidato para el tratamiento con un fármaco e RET, mediante el cual se pronosticar una probabilidad creciente de respuesta a un fármaco de RET. La invención proporciona un método para determinar la secuencia de RET. El método proporciona los cebadores de ARMS optimizados para determinar la secuencia de RET. La invención también proporciona un kit de diagnóstico, que comprende un cebador de ARMS.
MX2009002471A 2006-09-07 2007-09-06 Metodo para evaluar a pacientes para tratamiento con farmacos que detectan la transfeccion durante el redondeamiento (ret) de tirosina cinasa receptora. MX2009002471A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84276606P 2006-09-07 2006-09-07
PCT/GB2007/003335 WO2008029123A1 (en) 2006-09-07 2007-09-06 Method for evaluating patients for treatment with drugs targeting ret receptor tyrosine kinase

Publications (1)

Publication Number Publication Date
MX2009002471A true MX2009002471A (es) 2009-03-20

Family

ID=38829617

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009002471A MX2009002471A (es) 2006-09-07 2007-09-06 Metodo para evaluar a pacientes para tratamiento con farmacos que detectan la transfeccion durante el redondeamiento (ret) de tirosina cinasa receptora.

Country Status (12)

Country Link
US (1) US20110028498A1 (es)
EP (1) EP2064340A1 (es)
JP (1) JP2010502209A (es)
KR (1) KR20090048644A (es)
CN (1) CN101512017A (es)
AU (1) AU2007293280A1 (es)
BR (1) BRPI0716555A2 (es)
CA (1) CA2662591A1 (es)
IL (1) IL197157A0 (es)
MX (1) MX2009002471A (es)
NO (1) NO20090788L (es)
WO (1) WO2008029123A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8802384B2 (en) * 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
ES2841809T3 (es) * 2011-06-03 2021-07-09 Eisai R&D Man Co Ltd Biomarcadores para pronosticar y evaluar el grado de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
JP2014533508A (ja) * 2011-11-17 2014-12-15 リーアニクス・インコーポレイテッドＲｈｅｏｎｉｘ， Ｉｎｃ． 選択的分子分析のためのシステムおよび方法
BR112014027905A2 (pt) * 2012-05-14 2017-06-27 Genentech Inc anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico.
AU2014266223B2 (en) 2013-05-14 2020-06-25 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
JP6130755B2 (ja) * 2013-08-12 2017-05-17 ルネサスエレクトロニクス株式会社 半導体装置およびその製造方法
ES2926687T3 (es) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y método para su producción
HUE064614T2 (hu) 2015-02-25 2024-04-28 Eisai R&D Man Co Ltd Eljárás egy kinolin-származék keserû ízének elnyomására
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
AU2016279474B2 (en) 2015-06-16 2021-09-09 Eisai R&D Management Co., Ltd. Anticancer agent
WO2017134115A1 (en) * 2016-02-01 2017-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for determining responsiveness to vandetanib in a patient suffering from medullary thyroid carcinoma
CA3044056A1 (en) * 2016-11-30 2018-06-07 Exosome Diagnostics, Inc. Methods and compositions to detect mutations in plasma using exosomal rna and cell free dna from non-small cell lung cancer patients
CN109439752B (zh) * 2018-11-16 2022-02-15 上海派森诺医学检验所有限公司 一种鉴别甲状腺髓样癌ret基因突变的特异性引物组合及其试剂盒及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
ITMI20021620A1 (it) * 2002-07-23 2004-01-23 Novuspharma Spa Composto ad ativita' antitumorale

Also Published As

Publication number Publication date
CN101512017A (zh) 2009-08-19
CA2662591A1 (en) 2008-03-13
KR20090048644A (ko) 2009-05-14
JP2010502209A (ja) 2010-01-28
NO20090788L (no) 2009-03-13
EP2064340A1 (en) 2009-06-03
WO2008029123A1 (en) 2008-03-13
IL197157A0 (en) 2009-11-18
AU2007293280A1 (en) 2008-03-13
BRPI0716555A2 (pt) 2013-09-24
US20110028498A1 (en) 2011-02-03

Similar Documents

Publication Publication Date Title
MX2009002471A (es) Metodo para evaluar a pacientes para tratamiento con farmacos que detectan la transfeccion durante el redondeamiento (ret) de tirosina cinasa receptora.
HK1136943A1 (en) Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
EA201100621A1 (ru) Лечение диабета у пациентов, у которых наблюдается недостаточный гликемический контроль несмотря на лечение пероральным или непероральным противодиабетическим лекарственным средством
MX2009000385A (es) Acil-anilidas sustituidas y metodos de uso de las mismas.
EA201190053A1 (ru) Агонисты рецептора gpr120 и их применение
EA201170504A1 (ru) Арильные агонисты рецептора gpr120 и их применение
EA201100335A8 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
MX2009001962A (es) Acilanilidas substituidas y metodos de uso de las mismas.
WO2010003313A8 (zh) 埃克替尼盐酸盐及其制备方法、晶型、药物组合物和用途
EA200971077A1 (ru) Гетероциклические модуляторы киназы
EA201101037A1 (ru) Лечение диабета у пациентов с неадекватным гликемическим контролем, несмотря на лечение метформином
WO2011154139A3 (en) Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
NO20091413L (no) WNT-antagonister og deres anvendelse i diagnostiseringen og behandlingen av WNT-medierte forstyrrelser
WO2010124264A3 (en) Genetic variants in angiogenesis pathway associated with clinical outcome
EA201391074A1 (ru) Профили экспрессии генов рака толстой кишки и способы применения
NO20085099L (no) Puritonderivativer som HM74A agonister
WO2010059969A8 (en) Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer
TW200833688A (en) Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
CO6382138A2 (es) N-cadherina: blanco para diagnosis y terapia de cáncer
EA201071146A1 (ru) Способы диагностирования, предупреждения и лечения болезней, связанных с костной массой
WO2009122444A3 (en) Method for the diagnosis of higher- and lower-grade astrocytoma using biomarkers and diagnostic kit thereof
WO2006046270A3 (en) Nucleophosmin protein (npm) mutants, corresponding gene sequences and uses thereof
ATE529750T1 (de) Stimulatorische autoantikörper gegen den pdgf- rezeptor als pathologische marker und therapeutisches target
WO2011009908A3 (en) A method for predicting clinical outcome of patients with breast carcinoma
WO2010001369A3 (es) Métodos para el tratamiento y diagnóstico del cáncer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal